Introduction 52
The menopause is a universal physiological event related with the drop in ovarian hormone 53 secretions (oestrogens and progestin) that occurs as the stock of ovarian follicules is depleted. 54
Menopause is diagnosed when menstruation has stopped for 12 successive months, and the 55 average age at which it occurs is between 47 and 51 [1, 2] . Its clinical expression varies very 56 considerably between socio-cultural groups and individuals [3] . These variations depend on 57 many factors, such as women's social status, their nutrition, life style (smoking) and weight, 58 not forgetting genetic factors [3] . It is difficult to draw the distinction between the effects of 59 menopause and those of ageing. In addition to the menopausal "syndrome" itself, which 60 mainly comprises vasomotor symptoms and vaginal dryness, urinary symptoms including 61 incontinence (UI) have been attributed to menopause. The hormonal dependence of the 62 genital tract tissues has been evoked in order to explain the appearance of these female low 63 urinary tract symptoms (FLUTS) at the menopause. OEstrogen receptors have been found not 64 only in the pelvic floor muscles but also in the uro-genital ligaments and detrusor muscle cells 65 along with the connective tissues and all the fascias that maintain a stable relationship 66 between the various organs [2] . 67
Urinary incontinence can be defined as "the complaint of any involuntary leakage of urine" 68 [4] . The standard classification gives three main types of UI: Stress Urinary Incontinence 69 (SUI), Urge Urinary Incontinence (UUI) and Mixed Urinary Incontinence (MUI). Stress 70 urinary incontinence is characterised by involuntary loss of urine without any previous feeling 71 of a need to void, which takes place on the occasion of a physical stress (cough, lifting 72 something heavy, or any other physical activity). Urge urinary incontinence (or urgent need to 73 void) is characterised by involuntary loss of urine preceded by an urgent and irresistible need 74 to void resulting in uncontrollable leakage of urine. Mixed urinary incontinence is the 75 association in variable proportions of SUI and UUI. 76 UI may be experienced simply as a nuisance or as a real handicap [5, 6] . Women frequently 77 present the symptoms of UI, but the estimates for its prevalence in the general population vary 78 widely, from 8 to 30 %. This variability is due not only to the very heterogeneous nature of 79 the populations studied but also to the varying definitions of UI used in the studies. 80
Many different factors are associated with an increased risk of UI [7] . The main of these are 81 ageing, pregnancy, childbirth, past history of pelvic and perineal surgery, obesity, and chronic 82 pathologies (diabetes, cognitive problems, etc.). There is more debate about the roles of 83 menopause and hormone replacement therapy (HRT) [8, 9] . As mentioned above, it is difficult 84 4 to differentiate between the role of ageing and that of the menopause, and equally to 85 differentiate the true role of menopause from that of treatments instigated at the time of 86 menopause, such as HRT. 87
The relationship postulated between UI and hormone deficiencies induced by menopause is 88 based mainly on "physiological" data, i.e. the existence of (oestrogen and progestin) hormonal 89 receptors in the epithelial tissues of bladder, urethra and trigone and also in the vagina, 90 uterosacral ligaments, levator ani and puborectal muscles [10] . The other argument supporting 91 this relation is clinical observation of an increase in the prevalence of overactive bladder 92 (OAB) syndrome after the menopause. The lack of oestrogens could contribute in various 93 ways to other urinary symptoms that arise: oestrogens play a role in (i) the increase in 94 epithelial cellular trophicity in the vagina, urethra and bladder (ii) the increase in peri-urethral 95 vascularisation (an important factor for regulation of closing pressure), (iii) the increase in 96 maximum closing pressure and (iv) the increase in concentration and sensitivity of -97 adrenergic receptors with modification of the -adrenergic receptors/-adrenergic receptor 98 ratio in favour of the -adrenergic receptors [11] [12] [13] . Progestin receptors are also to be found 99 in the entire female genital tract, although in less constant fashion than oestrogen receptors. 100
Progestin appears to have a detrimental effect on continence, by reducing muscle tone of 101 bladder and urethra [10] . 102
The aim of our review is to analyse the data in the literature with respect to the relationship 103 between menopause and UI. We present the main epidemiological data dealing with the 104 relationship between prevalence, incidence and remission of UI, and the menopause. Among the 488 articles initially selected during the Medline search, 29 articles were finally 123 retained, including 3 meta-analyses, 4 literature reviews, 5 randomised controlled trials and 12 124 cohort studies. Figure 1 gives details on this selection of articles. 125 126 3.2.
Prevalence or incidence of UI according to age 127
The prevalence of urinary incontinence is proportional to age. The distribution of the various 128 types of UI changes with age.Several articles report a peak in the prevalence of SUI at midlife 129 (LE3). The majority of cases before the age of 50 are SUI, but after that age it represents a 130 minority [14] . After 60 it is mixed UI that predominates. The prevalence of UI at the time of 131 menopause varies from 8 to 27 % depending on the population studied and the definition used 132 for UI [14] [15] [16] [17] 
(LE2). 133
Only a few cohort studies specifically address the menopause period (45-60 years). There is considerable disparity between the cohort studies concerning the annual rate of 141 remission. On the one hand Hagglund [17] , Samuelsson [20] , and Townsend [19] report 142 annual remission rates for UI of 4, 6, and 7% respectively (LE3). On another hand other 143 authors report higher annual remission rates, at 25 to 29% [16, 18] Simultaneous cross-sectional and longitudinal analysis of the data did not reveal any 168 statistical relationship between UI and menopause (LE3). In the longitudinal analysis of 438 169 women from the same cohort who were followed for 7 years the menopause was not 170 associated with any increase in the incidence of UI as a whole (LE3) [15] . 171
The results obtained by another longitudianl study, the National Survey of Health and 172 Development (NSHD) concerning 1211 women between 48 and 54 years of age did not find 173 any association between menopause and UUI (LE3). SUI alone was associated with the 174 hormonal status, since in this study the peri-menopause was associated with an increased 175 prevalence of urine leakage symptoms due to stress, as compared with the group of post-176 menopausal women (OR= 1, 39 [1, 7] ) (LE3). This study, in which it is not possible to 177 distinguish clearly between the effects of age and those of menopause because there is no 178 comparison of the incidence rates between the different groups, nevertheless appears to reveal 179 7 an effect of ageing independent of that of the menopause with respect to the occurrence of 180 UUI or SUI (LE3) [23] . with tolterodine with that of tolterodine alone, found a significant improvement of objective 216 parameters and quality of life when oestrogens were associated with tolterodine (LE2) [30] . 217
Finally, a recent randomised trial comparing the efficiency of topical vaginal oestrogen 218 therapy with that of oxybutynin for the treatment of overactive bladder syndrome found that 219 the two products were similar in terms of efficiency (LE2) [31] . 220 A review of the literature covering eight controlled studies and 14 prospective non-controlled 221 studies concluded that oestrogen treatment is not efficient for SUI (LE2) [32] . 222 The data of the Nurses' Health Study addressing the impact of HRT on UI in a cohort of 252 nurses aged between 30 and 55 at the time of inclusion were analysed by Grodstein et al. [36] . 253
The occurrence of incident UI was associated in significant fashion with systemic hormone 254 therapy whatever the type of HRT and mode of administration: oral oestrogen (RR= 1.54 255 The results of our review concerning the link between menopause and UI do not all agree, but 287 this overview shows that the menopause has little if any impact on the risk of UI in general, 288 when confounding factors such as age or changes in weight are taken into account. It appears 289 that SUI decreases after the menopause while UUI or mixed UI increase at this time. Oral 290 HRT has a rather detrimental effect on stress urinary incontinence, by doubling the risk of de 291 novo SUI. Concerning UUI, HRT has less of an effect, which is variable according to the 292 population in question and the type of treatment. Topical vaginal oestrogen therapy is the only 293 treatment that seems to have a really beneficial effect on urge urinary incontinence or 294 overactive bladder symptoms. 295
Most of these results are drawn from longitudinal analyses of large cohorts enabling a 296 distinction to be drawn between the effect of age and that of the menopause. Longitudinal 297 studies are the only way to examine the timing, and consequently any cause and effect 298 relationship between events. Cross-sectional studies cannot assess time-dependent variables 299 such as age, weight and menopausal status. Nevertheless, the large cohort studies included in 300 this review present several problems. For example, the definition of UI is not identical in all 301 the studies because follow-up of the cohorts often started prior to the harmonisation of the 302 terminologies proposed by ICS and IUGA. The frequency of UI as a "functional complaint" 303 depends on the tools used. Moreover, few of the studies draw a distinction between the 304 various types of UI (SUI, UUI, MUI), their frequency or their severity. Finally in this type of 305 11 cohort, the lack of any overall assessment of incontinence risk factors (because the studies 306
were not designed initially to study this problem specifically) can result in confounding 307 biases. 308
Part of the results of this review is based on secondary analyses of randomised trials in which 309 the main objective was not to study UI but instead the cardiovascular morbidity of HRT. So 310 the level of evidence contributed by these secondary analyses is lower. 311
Certain pathophysiological data would tend to indicate a worsening of UI due to lack of 312 oestrogen. However, in contradiction with this postulate, the epidemiological data obtained 313 with the cohorts shows that the menopause has little if any effect on urinary symptoms. The 314 results of several large randomised trials in the general population reveal an aggravation of UI 315 in case of systemic HRT. This detrimental effect of HRT needs to be seen in the light of what 316 is observed during pregnancy, when an increase in the prevalence of UI is observed [42] . This 317 greater prevalence of UI during pregnancy could be explained by the increase in oestrogen 318
concentrations. 319
Topical vaginal oestrogen therapy alone appears to have a beneficial effect on overactive 320 bladder symptoms. This effect could be explained by the improvement in terms of vaginal 321 dryness and a drop in recurrent urinary infections [8, 11] . The learned societies do not 322 recommend the use of oestrogens (whether or not associated with progesterone) for the 323 treatment of UI. However, in case of overactive bladder symptoms in a post-menopausal 324 woman, topical vaginal treatment may be proposed [43, 44] . 325 326
Conclusion 327
Female urinary incontinence is a complex and dynamic phenomenon, related with age and a 328 many other factors that can change with time. In order to gain greater insight, longitudinal 329 studies are necessary, with several years or even decades of follow-up in order to clarify its 330 evolution and risk factors. 331
The onset and/or worsening of UI at the menopause that is expected on the basis of 332 physiological observations is not confirmed by the results of most of the epidemiological 333 studies that mostly cover a large number of women followed up over many years. Moreover, 334 correction of the lack of oestrogen by HRT gives rise to paradoxical results that depend on the 335 type of UI and mode of administration. Systemic oestrogen therapy results in an increase in UI 336
